Indeed, lncSLCO1C1 mediates tumour resistance to oxaliplatin as downregulation of lncSLCO1C1 re‐sensitised the platinum‐resistant tumour to fully response oxaliplatin treatment by reducing the interaction of SSRP1 with H2A/H2B and increasing the expression of γH2AX in tumour cells. Here, SSRP1 is linked to neoplasm.